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α5β1-Integrin promotes tension-dependent 
mammary epithelial cell invasion by engaging 
the fibronectin synergy site
ABSTRACT Tumors are fibrotic and characterized by abundant, remodeled, and cross-linked 
collagen that stiffens the extracellular matrix stroma. The stiffened collagenous stroma fos-
ters malignant transformation of the tissue by increasing tumor cell tension to promote focal 
adhesion formation and potentiate growth factor receptor signaling through kinase. Impor-
tantly, collagen cross-linking requires fibronectin (FN). Fibrotic tumors contain abundant FN, 
and tumor cells frequently up-regulate the FN receptor α5β1 integrin. Using transgenic and 
xenograft models and tunable two- and three-dimensional substrates, we show that FN-
bound α5β1 integrin promotes tension-dependent malignant transformation through en-
gagement of the synergy site that enhances integrin adhesion force. We determined that li-
gation of the synergy site of FN permits tumor cells to engage a zyxin-stabilized, vinculin-linked 
scaffold that facilitates nucleation of phosphatidylinositol (3,4,5)-triphosphate at the plasma 
membrane to enhance phosphoinositide 3-kinase (PI3K)-dependent tumor cell invasion. The 
data explain why rigid collagen fibrils potentiate PI3K activation to promote malignancy and 
offer a perspective regarding the consistent up-regulation of α5β1 integrin and FN in many 
tumors and their correlation with cancer aggression.
INTRODUCTION
Tumors are highly fibrotic (Van den Hooff, 1986; Walker, 2001; 
Lopez-Novoa and Nieto, 2009; Arendt et al., 2010; Ewald et al., 
2011; Samuel et al., 2011; Nakagawa et al., 2014). Fibrotic tumors 
contain abundant quantities of extracellular matrix (ECM) pro-
teins, such as type I collagen, fibronectin (FN), tenascin, and as-
sorted proteoglycans. Cancerous tissues also exhibit altered levels 
and activity of ECM receptors, including integrins, discoidin re-
ceptors, and syndecans (Ioachim et al., 2002; West et al., 2005; 
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(Kubow et al., 2009; Cox et al., 2013). The binding of FN to cross-
linked collagen increases the ability of fibroblasts to unfold FN to 
reveal cryptic binding sites, including the synergy site (Friedland 
et al., 2009; Seong et al., 2013), which is uniquely ligated by α5β1 
integrin (Garcia et al., 2002). Cells with FN-synergy site–bound α5β1 
integrin engage an adhesive bond that enables them to exert higher 
forces on their ECM (Friedland et al., 2009; Kong et al., 2009; Benito-
Jardon et al., 2017). Consistently, tumor cells sorted for higher cell-
surface α5β1 integrin are more contractile and migrate faster on a 
rigid FN ECM (Mierke et al., 2011). This suggests that a stiff, colla-
gen–FN-rich ECM may favor ligation of the FN synergy site by α5β1 
integrin to enhance integrin–growth factor receptor signaling that 
fosters malignancy. Here we used mouse models of mammary can-
cer, three-dimensional (3D) organotypic mammary epithelial cell 
(MEC) cultures, and a force reactor with quantitative analysis to ex-
plore the relationship between a stiff collagen ECM, FN ligation of 
the synergy site by α5β1 integrin, and tumor cell invasion.
RESULTS
Mammary tumor invasion colocalizes with collagen and FN 
fibers that decrease when stromal stiffening and malignancy 
are inhibited
We first determined whether an association exists between FN and 
ECM collagen stiffness–dependent mammary tumor invasion in 
vivo. We looked for colocalization of collagen and FN and tumor cell 
invasion in the mammary glands of late-stage FVB PyMT tumors that 
atomic force microscopy indentation previously revealed was signifi-
cantly stiffer than that of a normal mammary gland (normal gland: 
0.4 kPa, PyMT tumor: 3 kPa) (Lopez et al., 2011; Pickup et al., 2013). 
Confocal images of PyMT mammary tumor tissue immunostained 
for FN (Figure 1A, green) and imaged by second harmonic genera-
tion (Figure 1A, light blue) showed that a high percentage of in-
vading tumor cells (red) could be observed on thick collagen fibers 
that costained with FN (Figure 1A, quantified in Figure 1B). To im-
plicate FN in tension-dependent tumor invasion, we next analyzed 
mammary tissue from MMTV-Neu mice treated with (LOX-i) and 
without (control) the small-molecule inhibitor β-aminopropionitrile 
(BAPN) that inhibits LOX activity and that we previously showed 
prevents collagen cross-linking and ECM stiffening and reduces tu-
mor progression (Siegel, 1974; Kagan, 2000; Kirschmann et al., 
2002; Levental et al., 2009). Confocal imaging of mammary tumors 
from the BAPN-treated mice confirmed that the tumors had lower 
cell tension compared with their nontreated controls, as revealed by 
decreased immunostaining for myosin activity (Figure 1C, “pMLC,” 
green, quantified in Figure 1D), reflecting the decreased ECM stiff-
ness of the tissue (PyMT tumor: 3 kPa; PyMT tumor + BAPN: 0.1 kPa) 
(Levental et al., 2009; Lopez et al., 2011). Immunofluorescence im-
aging analysis further indicated that the BAPN-inhibited tumors had 
reduced integrin mechanosignaling (Dumbauld et al., 2010), as indi-
cated by lower levels of FAK phosphorylation at residue 397 (Figure 
1C, “p397FAK,” red, quantified in Figure 1D). Intriguingly, immuno-
staining showed that the BAPN-treated mice also had lower α2 
integrin (Figure 1C, “Integrin α2,” red) and α5 integrin (Figure 1C, 
“Integrin α5,” red), as well as reduced tissue FN (Figure 1C, “FN,” 
green, quantified in Figure 1D). These findings provide evidence of 
a plausible relationship among FN, collagen, and stiffness-depen-
dent tumor cell invasion
A link between the malignant phenotype of mammary 
tumors and expression of FN and its integrin receptors
To explore the possibility of a relationship between FN and the ma-
lignant phenotype of MECs, we conducted reconstituted basement 
Desgrosellier and Cheresh, 2010; Nam et al., 2010; Ozbek et al., 
2010; Gehler et al., 2013; Pickup et al., 2014; Theocharis et al., 
2015). Elevated β1-integrin levels and focal adhesion kinase (FAK) 
activity correlate positively with high tumor grade and predict for 
poor patient prognosis (Recher et al., 2004; dos Santos et al., 
2012; Sulzmaier et al., 2014). Inhibiting β1-integrin ligand binding 
represses the malignant phenotype of tumor cells in vitro and in 
vivo (Weaver et al., 1997; Stoeltzing et al., 2003; Huang et al., 
2011; Blandin et al., 2015), and transgenic ablation of β1 integrin 
or FAK prevent oncogene-induced malignant transformation and 
metastasis (van Nimwegen et al., 2005). Function-blocking anti-
bodies to integrins and FAK inhibitors are also under clinical con-
sideration to improve the treatment of fibrotic tumors (Walsh 
et al., 2010; Stokes et al., 2011; Lagares et al., 2012; Jiang et al., 
2016). These findings emphasize the interplay among tissue fibro-
sis, the ECM, and integrin signaling in malignancy.
Tumors are mechanically corrupted tissues with high interstitial 
pressure, elevated compression, increased solid stress, ECM stiffen-
ing, and increased cellular tension (Heldin et al., 2004; Paszek et al., 
2005; Levental et al., 2009; Lopez et al., 2011; Samuel et al., 2011; 
Provenzano et al., 2012; Mouw et al., 2014; Laklai et al., 2016). 
Fibrotic tumors contain a stiffened ECM, which associates with can-
cer aggression and high patient mortality (Shimosato et al., 1980; 
Maeshima et al., 2002; Willis and Borok, 2007; Levental et al., 2009; 
Egeblad et al., 2010). Elevating tumor cell contractility (tension) or 
stiffening the tumor ECM through increased deposition, remodel-
ing, and cross-linking of type 1 fibrillar collagen promotes the malig-
nant transformation and aggressiveness of a tumor tissue in culture 
and in vivo (Paszek et al., 2005; Levental et al., 2009; Kraning-Rush 
et al., 2012; Acerbi et al., 2015; Laklai et al., 2016). Moreover, reduc-
ing cell tension or interstitial pressure or preventing matrix stiffening 
by inhibiting collagen cross-linking decreases tumor incidence and 
aggression and can improve treatment efficacy (Paszek et al., 2005; 
Levental et al., 2009; Samuel et al., 2011; Provenzano et al., 2012; 
Chauhan et al., 2013; Miller et al., 2015). Cell tension and ECM stiff-
ness promote focal adhesion assembly, and β1-integrin ligation and 
signaling is necessary for tension-dependent malignant transforma-
tion and tumor metastasis (Paszek et al., 2005; Levental et al., 2009; 
Samuel et al., 2011; Pickup et al., 2013; Kaushik et al., 2016). What 
remains unclear is whether tissue mechanics promote malignancy 
and tumor aggression by engaging specific β1-integrin heterodi-
mers, and if so, why? Indeed, while thick perpendicular collagen fi-
bers associate with invasive cancers (Provenzano et al., 2006; Leven-
tal et al., 2009; Conklin et al., 2011; Carey et al., 2012), and a 
stiffened collagen ECM can promote malignant transformation in 
culture (Paszek and Weaver, 2004; Levental et al., 2009; Mirosh-
nikova et al., 2011; Cassereau et al., 2015), the major collagen re-
ceptor, α2β1 integrin, inhibits rather than promotes malignancy in 
vivo (Zutter et al., 1995; Ramirez et al., 2011).
FN is frequently elevated in primary and metastatic tumors (Nam 
et al., 2010), and the premetastatic niche contains abundant FN 
(Kaplan et al., 2005). Moreover, expression of the major FN receptor 
α5β1 integrin is increased in many solid primary tumors, and the 
levels of either FN or α5β1 integrin independently correlate with 
poor prognosis in cancer patients (Yao et al., 2007; Dingemans et al., 
2010; Nam et al., 2010). Functionally, ligated α5β1 integrin pro-
motes tumor cell growth and survival, and blocking FN ligation by 
soluble tripeptide composed of l-arginine, glycine, and l-aspartic 
acid (RGD) sensitizes breast tumor spheroids to radiation treatment 
(Park et al., 2006; Nam et al., 2010; Yao et al., 2016). Importantly, FN 
can be coassembled with type I collagen (Sevilla et al., 2013), and 
lysyl oxidase (LOX)-dependent collagen cross-linking requires FN 
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colonies, lacking apical-basal polarity and stable cell–cell adhesions 
(Figure 2A, middle). Flow-activated cell sorting (FACs) revealed that 
the HMT-3522 T4-2 cells in this series express significantly higher 
plasma membrane levels of the FN integrin receptors αv and α5 and 
β1 (Figure 2B), whose levels were confirmed by immunoblot analysis 
of protein isolated from 3D rBM colonies (Figure 2C). Organotypic 
rBM cultures also revealed that only the tumor colonies deposited FN 
in the 3D rBM assay (Figure 2A, middle, “Fibronectin”). Importantly, 
inhibiting β1-integrin ligand binding, using the ligand function–
blocking antibody (AIIB2; Weaver et al., 1997) or by pharmacologi-
cally inhibiting the activity of the epidermal growth factor receptor 
(EGFR) by treating the cultures with tyrphostin (Wang et al., 1998), 
membrane (rBM) mammosphere assays using the immortalized MEC 
tumor progression series HMT3522 (Weaver et al., 1996, 1997). As 
previously reported, the nonmalignant S1 MECs in this tumor-pro-
gression series formed growth-arrested polarized acini when grown 
within a 3D rBM for 2 wk (Weaver et al., 1997; Wang et al., 1998; Rizki 
et al., 2008). The polarized acini phenotype was indicated by apical-
lateral cortical actin (phalloidin, green, Figure 2A), cell–cell-localized 
β-catenin (β-catenin, green, Figure 2A, left) and basally localized β4 
integrin (Figure 2A, left). The S1 MECs also assembled an endoge-
nous basement membrane, as indicated by basally deposited lam-
inin 5 (Laminin V) (Figure 2A, left). By comparison, the malignant T4-2 
MECs formed continuously growing (unpublished data), tumor cell 
FIGURE 1: Mammary tumor invasion colocalizes with collagen and FN fibers that decrease when stromal stiffening and 
malignancy are inhibited. (A) Zoomed-in second harmonic generation images of collagen (blue), FN (green), and nuclei 
(red), as well as an overlay in the 7-mo-old PyMT tumors at the invasive front (left four images) evident from the 
zoomed-out overlay image (rightmost image). Scale bar: 20 μm. (B) Quantification of cells migrating along FN-coated vs. 
non–FN-coated collagen fibers. (C) Confocal immunofluorescence images of mammary tissue stained for p397FAK, pMLC, 
FN, and α2 integrin, αv integrin, and α5 integrin in tissue excised from 7-mo-old control (Her2/Neu) or LOX inhibitor–
treated (+LOX-i) Her2/Neu transgenic mice with quantification of fluorescence intensity in D. Scale bar: 10 μm. Results 
are the mean ± SEM of three separate experiments. For animal studies, three animals were used per condition with 
three to five images per animal analyzed for quantification. *, p < 0.05; ***, p < 0.001.
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reverted tumor colonies had basally local-
ized β4 integrin (Figure 2A, right, “β4 integ-
rin,” green) and assembled an endogenous 
basement membrane, as revealed by basally 
deposited laminin 5 (Figure 2A, right, “Lam-
inin V,” green). Interestingly, the reverted 
tumor colonies no longer secreted FN into 
the 3D rBM (Figure 2A, right, “Fibronectin,” 
green) and an immunoblot of total colony 
protein showed a dramatic reduction of inte-
grin α5, α2, and β1 in the reverted acini 
(Figure 2C). These findings establish a causal 
association between FN and its integrin re-
ceptors α5, αv, and β1 and expression of the 
malignant phenotype of mammary tissue–
like structures in 3D rBM culture.
FN-ligated α5β1 integrin regulates the 
malignant phenotype of MECs in vitro 
and in vivo
We next asked whether FN ligation by ei-
ther of its integrin receptors, α5 or αv, influ-
enced the malignant phenotype of MEC 
HMT-3522 tumor cells. We treated the 
HMT-3522 T4-2 MECs, which secrete FN 
(see Figure 2A), with either α5- or αv-
integrin function–blocking antibodies and 
assayed for changes in cell growth and col-
ony morphology after 2 wk within rBM com-
pared with the effect of blocking the activity 
of α2, α3, or β1 integrin. Blocking ligand 
binding to αv (Figure 3A, second column), 
α2 (Figure 3A, third column), or α3 integrin 
(unpublished data) had little to no effect on 
the growth and morphological behavior of 
the T4-2 MECs in a 3D rBM. However, inhib-
iting α5  integrin repressed the malignant 
phenotype of the T4-2 MECs in rBM (Figure 
3A, fourth column), similar to what was ob-
served following inhibition of β1-integrin li-
gand binding (Figure 3A, fifth column; see 
also Figure 2A). After 2 wk of culture within 
rBM the T4-2 MECs treated with either im-
munoglobulin G (IgG) isotype–matched 
control or inhibitory antibodies to α2 or αv 
integrin formed continuously growing, 
large, disorganized, and invasive colonies in 
rBM, as indicated by disorganized β-catenin 
(Figure 3A, top), α6 integrin (Figure 3A, 
middle), and actin (Actin; Figure 3A, bot-
tom). By contrast, the T4-2 MECs treated 
with function-blocking antibodies against 
either α5 or β1 integrin assembled morpho-
logically reverted colonies in rBM that were reminiscent of differenti-
ated nonmalignant S1 mammary acini (Figure 2A). T4-2 MECs in 
which α5β1 integrins were inhibited assembled growth-arrested 
(unpublished data), polarized structures as indicated by cell–cell-lo-
calized β-catenin (Figure 3A; top panel), basal α6 integrin (Figure 
3A, middle), and apical-lateral cortical actin (Figure 3A, bottom). 
The reverted T4-2 MECs also formed acini that were at least 60–
70% smaller than the nonreverted colonies (Figure 3B). Moreover, 
preventing α5- or β1-integrin ligand binding significantly impaired 
reverted the invasive colony phenotype of the T4-2 MECs toward 
that of the differentiated nonmalignant S1 MECs (Weaver et al., 
1997; Weigelt et al., 2014). Thus the reverted T4-2 MECs formed 
growth-arrested (unpublished data), apically-basally polarized acini 
after 2 wk of growth within a 3D rBM (Figure 2A, right). Confocal im-
ages of immunofluorescently stained cultures showed that the re-
verted tumor colonies had apical-lateral cortical actin (Figure 2A, 
right, “F-actin,” green) and cell–cell-localized β-catenin (Figure 2A, 
right, “β-catenin,” green). Immunostaining also revealed that the 
FIGURE 2: Link between the malignant phenotype of mammary tumors and expression of FN 
and its integrin receptors. (A) Phase-contrast and confocal immunofluorescence images of Ki-67 
(insert), phalloidin (F-actin), β-catenin, β4 integrin, laminin-5, and FN-stained colonies of 
nonmalignant (S-1), malignant (T4-2), and phenotypically reverted (T4 Rvt) HMT-3522 human 
MECs grown within an rBM for 2 wk. Scale bar: 10 μm. (B) Bar graphs of FACS analysis of 
membrane-localized integrins in S-1 compared with T4-2 MECs. (C) Representative immunoblot 
image of α5, αv, and β1 integrin in lysates from S-1, T4-2, and T4 Rvt 3D rBM colonies shown in 
A with corresponding quantification of signal intensity normalized to E-cadherin loading control. 
Fifty acini were analyzed in three separate experiments. ***, p < 0.001.
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FIGURE 3: FN-ligated α5β1 integrin regulates the malignant phenotype of MECs in vitro and in vivo. (A) Confocal 
immunofluorescence images of β-catenin, α6 integrin, and actin (Phalloidin) staining of malignant (T4-2) MEC colonies 
grown for 2 wk in rBM in the presence of a function-blocking antibody (mAb) to αv, α2, α5, or β1 or an IgG isotype–
matched control mAb. Scale bar: 30 μm. (B) Bar graph showing relative size of the T4-2 colonies shown in A. (C) Bar 
graph showing percentage of tumor colonies formed in soft agar (40+ microns) following treatment with function-
blocking mAbs to αv, α2, α5, or β1 integrin or an IgG isotype–matched control mAbs. (D) Mean fluorescence intensity 
of integrin α2 and α5 expression in S-1 cells overexpressing Itga2. (E) Mean fluorescence intensity of integrin α2 and 
α5 expression in S-1 cells overexpressing Itga5. (F) Confocal immunofluorescence images of β-catenin, β4 integrin, and 
collagen IV staining of colonies of nonmalignant (S-1) vector (Ctrl) MECs and MECs expressing elevated α2 or α5 
integrin grown in rBM with or without the addition of FN (+FN) for 2 wk. Scale bar: 10 μm. (G) Bar graph showing 
relative size of S-1 MEC colonies shown in D. (H) Bar graph showing percent Ki-67–positive S-1 MEC colonies shown in 
D. (I) Bright-field images of low (top) and high (bottom) magnification of H&E sections of tissue excised 2 mo following 
injection of malignant T4-2 MECs with IgG or a function-blocking antibody to α5 integrin and nonmalignant S-1 MECs 
expressing empty vector or an α5 integrin. Scale bar: 10 μm. Red arrows indicate areas of necrosis observed upon 
blocking of integrin a5. Red arrows indicate hyperplastic or dysplastic cellular structures. (J) Table summarizing tumor 
score and histological features. Scale bar: 10 μm. **, p < 0.01; ***, p < 0.001.
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elevated proliferating cell nuclear antigen (PCNA) immunostaining, 
negligible activated caspase 3 immunostaining, a clearly visible vas-
culature (confirmed by CD34 immunostaining), and histopathological 
analysis that confirmed the presence of invasive cell masses (Figure 3, 
I and J, green arrows indicate proliferating cells, and Supplemental 
Figure 1C, left panels). By comparison, T4-2 cells treated with the α5-
integrin function–blocking antibody formed only small, nonproliferat-
ing tumor colonies that immunostained positively for the apoptosis 
marker–activated caspase 3. The tumors formed by the cells treated 
with the α5-integrin function–blocking antibody also lacked a vascula-
ture (Supplemental Figure 1D, top left panels), as revealed by negli-
gible CD34 immunostaining (Supplemental Figure 1D, bottom left 
panels), and they showed histopathological evidence of cystic degen-
eration and necrosis (Figure 3, I and J, red arrows indicate dying cells, 
and Supplemental Figure 1C, right panels). As expected, the majority 
of the injected nonmalignant S1 MECs failed to survive (red arrow in-
dicate dying cells), and those that did formed ductal-like differenti-
ated tissue-like structures (Figure 3I, zoom, see arrows; Figure 3J). By 
contrast, those S1 MECs expressing high levels of α5 integrin not only 
survived, but they grew to form hyperplastic/dysplastic cell masses 
that apparently induced an angiogenic response, as indicated by a 
visible vasculature and positive CD34 tissue immunostaining (Figure 
3, I and J, green arrows point to proliferating cells, and Supplemental 
Figure 1D, top and bottom right panels). These in vivo tumor studies 
suggested that engagement of α5β1 integrin by MECs might stimu-
late tumor angiogenesis, another key feature attributed to a malig-
nant tissue (Pickup et al., 2014). To directly address this possibility, we 
grew the nonmalignant S-1 MECs ectopically expressing α5 integrin 
or α2 integrin within a 3D rBM doped with either type I collagen or FN 
inside of a tissue culture insert until they formed colonies (10–12 d 
culture). The tissue culture inserts containing the rBM/FN-embedded 
MEC colonies were then transferred into a Transwell in which vascular 
endothelial cells were grown on the bottom to semiconfluence and 
then overlaid with a layer of type I collagen (Supplemental Figure 1A). 
The growth and invasion of the vascular endothelial cells into the col-
lagen gel was then monitored over several days, and extent of net-
work formation was quantified (60 d). Consistent with the in vivo find-
ings, we noted that the colonies formed by the nonmalignant MECs 
expressing FN-ligated α5 integrin, but not collagen-ligated α2 integ-
rin, induced more endothelial network-like structures (Supplemental 
Figure 1B, top left bar graphs). We next conducted a similar endothe-
lial network assay using the malignant HMT-3522 T4-2 MECs incu-
bated with IgG control antibody or function-blocking antibodies 
against α2, αv, α5, or β1 integrin. Findings showed that only the T4-2 
colonies incubated with the IgG control or the α2- or αv-integrin func-
tion–blocking antibodies were able to stimulate a significant amount 
of vascular network formation (Supplemental Figure 1B) compared 
with those tumor cells that had been phenotypically reverted by 
blocking either α5- or β1-integrin function (Supplemental Figure 1B, 
top right bar graphs). Consistent with these findings, enzyme-linked 
immunosorbent assay (ELISA) revealed that only the FN-ligated α5β1-
integrin MECs expressed abundant vascular endothelial growth factor 
(VEGF), and that inhibiting α5 or β1 integrin in the malignant T4-2 
MECs significantly reduced levels of tumor-secreted VEGF (Supple-
mental Figure 1B, bottom right and left bar graphs). These findings 
indicate that FN-ligated α5β1 integrin can regulate the malignant 
phenotype of mammary tissues both in vitro and in vivo.
FN-ligated α5β1 integrin increases cell tension to promote 
mammary malignancy
We next determined whether the ability of FN ligation of α5β1 inte-
grin to promote the malignant behavior of mammary tissues 
the anchorage-independent growth and survival of the T4-2 MECs 
in soft agar (Figure 3C). These data suggest that FN-ligated α5β1 
integrin regulates expression of the malignant phenotype of the 
T4-2 MEC in a 3D rBM.
We next investigated whether FN-ligated α5β1 integrin could 
promote the malignant phenotype of nonmalignant MECs. HMT-
3522 S1 nonmalignant MECs (which express negligible α5 integrin) 
were engineered to express either a tetracycline (Tet)-regulated en-
hanced green fluorescent protein (eGFP)-tagged α5 integrin or an 
eGFP-tagged α2 integrin. Immunoblot and FACS analysis confirmed 
a Tet-modulated increase in total and cell-surface α5 integrin and α2 
integrin in two independent nonmalignant HMT-3522 S1 MEC lines 
(Figure 3, D and E) and two independent nonmalignant MCF10A 
MEC lines (Damiano et al., 2014). Neither ectopic expression of α5 
integrin nor α2 integrin significantly altered plasma membrane lev-
els of α1, α2, α3, α6, β1, or β4 integrin in either the HMT-3522 S1 or 
the MCF10A MECs (unpublished data). Furthermore, MCF10A 
MECs expressing elevated levels of α5 integrin showed greater ad-
hesion to FN, and those engineered to express high α2 integrin 
adhered more to a type I collagen ECM (Damiano et al., 2014). The 
nonmalignant S1 MECs expressing either more α2 integrin or α5 
integrin assembled growth-arrested (Figure 3F), polarized acini with 
a cleared central lumen after 10–14 d of growth within rBM. This 
“normal” phenotype was indicated by immunofluorescence stain-
ing, which revealed cell–cell-localized β-catenin (Figure 3F, top), ba-
sally localized β4 integrin (Figure 3F, middle), and basally deposited 
collagen IV (Figure 3F, bottom). Importantly, when the α5 integrin 
was ligated through addition of FN to the rBM, the HMT-3522 S1 
MECs expressing ectopic α5 integrin formed continuously growing 
colonies (Figure 3, G and H) that by 2 wk were almost double the 
size of the colonies formed by the non–FN-ligated α5 integrin–ex-
pressing S1 MECs (Figure 3G). The FN-ligated α5 integrin–express-
ing S1 MEC colonies were unable to clear their lumens (Figure 3F), 
showed diffuse cell–cell-localized β-catenin (Figure 3D, top) and 
disorganized β4 integrin (Figure 3F, middle), and failed to assemble 
an endogenous collagen IV basement membrane (Figure 3F, bot-
tom). In the presence of exogenous FN, nonmalignant S1 MECs ex-
pressing elevated cell-surface α5 integrin formed colonies that were 
30-40% larger than the S1 MECs expressing higher α2 integrin, de-
spite the availability of abundant collagen (Figure 3G). We observed 
a similar tumor-promoting phenotype following FN ligation in the 
nonmalignant immortalized MCF10A MECs ectopically engineered 
to express higher α5-integrin levels (Figure 4A) (Damiano et al., 
2014) with little to no effect on tissue phenotype following collagen 
ligation of MCF10A MECs expressing higher α2-integrin levels 
(Figure 4A). These findings demonstrate that FN-ligated α5β1 inte-
grin can promote the malignant phenotype of nontransformed MEC 
tissue-like structures in vitro, reminiscent of prior studies implicating 
FN ligation on acinar morphogenesis and growth of MCF10A 
(Williams et al., 2008).
To further implicate FN ligation of α5β1 integrin in the malignant 
behavior of mammary tissues, we manipulated α5-integrin expression 
and function in nonmalignant and malignant MECs and assayed for 
effects on their malignant behavior in vivo. We inoculated nonmalig-
nant HMT-3522 S1 MECs expressing eGFP (nonmalignant control) or 
α5 integrin (+α5 integrin), and HMT-3522 T4-2 malignant MECs 
treated with either an α5-integrin function–blocking monoclonal anti-
body (α5-integrin inhibited) or an isotype IgG control antibody (tumor 
control), into the rear flanks of BALB/c nu/nu mice. Two months fol-
lowing MEC inoculation, the mice were killed and the tumor pheno-
type was assessed. The control tumors had formed large, actively 
growing, invasive, and angiogenic tumor masses, as indicated by 
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FIGURE 4: FN-ligated α5β1 integrin increases cell tension to promote mammary malignancy. (A) Phase-contrast and 
confocal immunofluorescence images of β1 integrin, phalloidin (F-actin), laminin V, Ki-67 and activated caspase 3 
(Caspase-3), and DAPI (nuclei)-stained colonies of nonmalignant (MCF10A) human MECs expressing empty vector or 
elevated α2 or α5 integrin treated with or without a ROCK inhibitor and malignant cells (HMT-3522 T4-2) incubated with 
nonspecific IgG or function-blocking antibodies to α2 or α5 integrin or treated with or without a ROCK inhibitor grown 
within a collagen gel with added FN for 2 wk. Scale bar: 8 μm. (B) Bar graph showing relative size of the nonmalignant 
colonies shown in A. (C) Bar graph showing relative size of the malignant colonies shown in A. (D) Immunofluorescence 
confocal images (bottom) and phase-contrast images (top) of 3D cultures of α2/Col 1 and α5/FN nonmalignant MECs 
stained for the ROCK target p696MYPT (top). Scale bar: 50 μm. (E) Second harmonic generation images of nonmalignant 
(MCF10A) human mammary epithelial day 20 acini (green) expressing empty vector or elevated α5 integrin with or 
without FN embedded in collagen (blue) and installed into a 3D tension bioreactor system and subjected either to 0% 
(400 Pa) or 10% (4000 Pa) stretch, as described previously (Cassereau et al., 2015). Arrows in E indicate invasive cells 
and colony circularity (left) and area (right) are quantified in F. Results are the mean ± SEM of three to five separate 
experiments. **, p < 0.01; ***, p < 0.001. (Ten to 15 acini were analyzed per condition in three separate experiments.)
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integrin was also illustrated by a set of invasion-monitoring studies 
that employed the 3D tension bioreactor with and without added 
FN. The 3D tension bioreactor permits the rapid stiffening of the 
ECM from 400 to 4000 Pa through the application of a uniaxial 
stretch (Cassereau et al., 2015). Findings revealed that nonmalig-
nant MCF10A control preassembled MEC colonies embedded 
within a nonstiffened 3D collagen–rBM remained quiescent and 
noninvasive for 48 h, as indicated by retention of colony circularity 
(Figure 4F). Upon uniaxial stretch and collagen stiffening, the non-
malignant MECs still did not invade, although they did begin to 
project membrane protrusions (Figure 4, E and F). MEC colonies 
ectopically expressing higher α5 integrin exhibited a similar pheno-
type to that demonstrated by the vector control and α2 integrin–
overexpressing MECs when embedded within the relaxed and 
stretched, collagenous 3D tension bioreactor, nevertheless their 
protrusion activity was enhanced (Figure 4, E and F). However, and 
importantly, addition of FN to the 3D tension bioreactor significantly 
enhanced the protrusive behavior of the control mammary colonies 
and induced the rapid and significant invasion of the MEC colonies 
ectopically expressing the higher cell-surface α5 integrin (Figure 4E, 
compare with and without FN, see white arrows). These findings 
imply that FN ligation of α5β1 integrin could promote the malignant 
behavior of mammary tissues by enhancing tumor cell tension.
FN-ligated α5β1 integrin and not collagen-ligated α2β1 
integrin increases MEC tension
We next asked whether FN-ligated α5β1 integrin induced more ac-
tomyosin tension in the nonmalignant MECs and whether this modi-
fied their integrin adhesions (Regent et al., 2011). Collagen–FN gel 
contraction assays revealed that both the nonmalignant HMT-3522 
and MCF10A MECs ectopically expressing higher α5 integrin con-
tracted 3D collagen–FN gels better than the MECs engineered to 
express higher α2 integrin (Supplemental Figure 2). These findings 
were verified by traction force microscopy (TFM) which directly 
demonstrated that the nonmalignant MECs ectopically expressing 
higher α5 integrin exerted higher maximum cell traction force on an 
FN ECM, as compared with nonmalignant MECs ectopically ex-
pressing α2 integrin plated on collagen I ECM (Figure 5, A and B). 
The nonmalignant MECs expressing more α5 integrin that were 
plated on FN also showed significantly higher levels of nuclear yes-
associated protein (YAP), reflecting enhanced activity of the mech-
ano-activated Hippo pathway (Aragona et al., 2013), as compared 
with the nonmalignant MECs expressing higher α2 integrin plated 
on collagen I (Figure 5C, quantified in Figure 5D). Indeed, the FN-
ligated nonmalignant MECs expressing higher α5β1 integrin as-
sembled more and apparently larger peripheral integrin adhesions 
(Figure 5E) that stained strongly with p397FAK (Figure 5E, quantified 
in Figure 5F). Immunostaining also showed that MECs with FN-li-
gated α5β1 integrin recruited more of the force-activated molecules 
vinculin (Figure 5G, quantified in Figure 5H) and zyxin (Figure 5I, 
quantified in Figure 5J) to their ECM adhesions, as compared with 
MECs with collagen 1-ligated α2β1 integrin (Figure 5, E–J). These 
findings show that FN ligation of α5β1 integrin induces a greater 
amount of actomyosin tension in MECs at their ECM adhesions. The 
higher FN-ligated α5β1-integrin adhesion force in turn permits the 
assembly of tension-regulated scaffolding molecules and enhances 
mechano-signaling through YAP.
FN-ligated α5β1 integrin enhances mechanotransduction 
in MECs
Unlike αv integrin, α5 integrin binds to both the proline-histidine-
serine-arginine-asparagine (PHSRN) synergy and RGD sites of FN, 
depended on cell tension. We treated 3D collagen–FN cultures of 
the nonmalignant MCF10A MECs engineered to express higher 
cell-surface α5 integrin or α2 integrin, with either a ROCK inhibitor 
(Y27632, 10 µM) (Figure 4A) or a myosin inhibitor (blebbistatin; un-
published data). Two weeks following embedment within a 3D col-
lagen–rBM–FN hydrogel, vector control, nonmalignant MCF10A 
MECs, and the MCF10A MECs ectopically expressing higher α2 in-
tegrin assembled growth-arrested (Figure 4A, bottom, “Ki-67”), tis-
sue-like structures (Figure 4A, top, DIC phase-contrast images) that 
resembled acini. Confocal immunofluorescence images confirmed 
that both the MCF10A vector control, and α2 integrin–overexpress-
ing MEC acini were polarized. Colony phenotype was indicated by 
apical-lateral cortical actin (Figure 4A, second row, “β1 integrin,” 
“F-actin,” and “DAPI”); deposition of an endogenous basally local-
ized, basement membrane (Figure 4A, third row, “Laminin V”); and 
lumen clearance, indicated by detectable apoptotic cells in the col-
ony core (Figure 4A, bottom row, activated “Caspase-3” and 
“DAPI”). By contrast, the MCF10A MECs ectopically expressing 
higher α5 integrin formed continuously growing, disorganized colo-
nies lacking a central lumen (Figure 4A, third column) that were sig-
nificantly larger than those formed by either the vector control or α2 
integrin–overexpressing MECs (Figure 4B). Critically, treatment of 
the MCF10A MEC α5 integrin–overexpressing MEC colonies with 
ROCK inhibitor phenotypically reverted the colonies so they resem-
bled growth-arrested, differentiated acini, with a size and organiza-
tion that resembled the vector control MCF10A MEC acini (Figure 
4A, compare fourth to first column, and Figure 4B). These findings 
suggest FN ligation of α5β1 integrin promotes a tumor phenotype 
in MECs by increasing cell tension. Consistent with this notion, im-
munostaining revealed that the FN-ligated MECs expressing higher 
α5 integrin, but not the collagen-ligated MECs expressing higher 
α2 integrin, stained positively for activity of the ROCK target, myo-
sin phosphatase binding protein (MyPT) (p696MyPT) (Figure 4D). 
Similarly, treating the malignant HMT-3522 T4-2 MECs that overex-
pressed α5β1 integrin (Figure 2), which we previously showed had 
elevated RhoGTPase and ROCK activity (Paszek et al., 2005), with 
the same ROCK inhibitor, also reverted their tissue phenotype to-
ward that resembling the nonmalignant MCF10A MECs or the T4-2 
MECs incubated with an α5-integrin function–blocking antibody 
(Figure 4A, compare fifth through seventh columns with eighth col-
umn). The T4-2 MECs treated with the ROCK inhibitor assembled 
smaller (Figure 4C), growth-arrested (Figure 4D, bottom row), polar-
ized acini (Figure 4A) that were similar to those generated in the 
presence of a function-blocking antibody to α5 integrin (Figure 4A, 
right). In marked contrast, the T4-2 MECs generated by the IgG 
isotype–treated control tumors or those in which α2 integrin was 
inhibited formed larger (Figure 4C), proliferative, invasive, and dis-
organized colonies (Figure 4A, right). These findings suggest that 
the ability of FN ligation of α5β1 integrin to promote the malignant 
behavior of mammary tissues, in vitro at least, depends on cell 
tension.
We next confirmed whether links between tissue tension and 
FN-ligated α5β1 integrin and expression of the malignant pheno-
type of mammary tissues existed by manipulating ECM stiffness to 
increase cell tension. Consistent with an enhancement of stiffness-
induced induction of cell tension, we observed that MECs ectopi-
cally expressing α5 integrin, as opposed to those ectopically ex-
pressing high αvβ3 integrin, demonstrated strong directional 
migration (Isenberg et al., 2009; Hartman et al., 2016) in response to 
a gradient of FN stiffness, or those ectopically expressing α2 integ-
rin in response to a gradient of collagen I stiffness (Supplemental 
Figure 3C). The impact of ECM stiffness and FN ligation of α5β1 
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expressing higher α5 integrin bound with at least twice as much 
strength to a recombinant wild-type 9–10 domain of FN compared 
with MECs ectopically expressing αvβ3 integrin ligated to the same 
9–10 domain of FN. The enhanced ligand binding strength de-
pended on synergy-site binding by α5β1 integrin, because the 
strength of adhesion decreased significantly when the synergy-site 
region in the 9–10 domain of FN was mutated. Given these findings 
and prior work emphasizing differential roles of FN domains during 
fibrillogenesis (Sechler et al., 1997), we further explored the rele-
vance of FN domains on cell tension generation. We first observed 
that the size of the integrin adhesions and the amount of p397FAK 
and only FN-bound α5β1 integrin, but not αvβ3 integrin, exhibits a 
unique adhesive bond phenotype in which ligand binding is rein-
forced in response to force (Friedland et al., 2009; Cao et al., 2012; 
Seong et al., 2013). Consistently, shear-force adhesion studies 
showed that nonmalignant MECs engineered to ectopically express 
high levels of α5 integrin attached to either full-length (unpublished 
data) or a recombinant 9–10 domain FN, bound with much greater 
strength as compared with MECs plated on recombinant 9–10 do-
main FN in which the PHSRN domain was mutated (Figure 6A and 
Supplemental Figure 3B), as previously shown in fibroblasts and 
CHO cells (Gallant and Garcia, 2007; Friedland et al., 2009). MECs 
FIGURE 5: FN-ligated α5β1 integrin and not collagen-ligated α2β1 increases MEC cell tension. (A) Force maps of α2/
Col 1 and α5/FN nonmalignant MECs and bar graphs (B) showing maximum traction generated by MECs at the cell 
edge. (C) Immunofluorescence images of α2/Col 1 and α5/FN nonmalignant MECs stained for YAP (arrow 
indicating nuclear localization of YAP). Scale bar: 15 μm. (D) Bar graphs quantifying percent nuclear YAP in MECs 
shown in H. Results are the mean ± SEM of three separate experiments with 10–15 acini analyzed per condition. 
(E) Immunofluorescence confocal images of nonmalignant MECs expressing either exogenous α2 integrin plated 
on type I collagen (α2/Col 1) or exogenous α5 integrin plated on FN (α5/FN) stained for p397FAK (green) or with 
phalloidin (F-actin; red). Scale bar: 10 μm. (F) Bar graph quantifying size of peripheral adhesions shown in E. 
(G) Immunofluorescence confocal images of α2/Col 1 and α5/FN nonmalignant MECs stained for vinculin (red). Scale 
bar: 3 μm. (H) Bar graphs showing quantification of relative amount of vinculin recruited to focal adhesions in MECs 
shown in G. Quantification is relative to α5-overexpressing cells on FN-coated matrices. (I) Immunofluorescence 
confocal images of α2/Col 1 and α5/FN nonmalignant MECs stained for zyxin (green). Scale bar: 3 μm. (J) Bar graphs 
showing quantification of relative zyxin recruited to focal adhesions in MECs shown in I. Quantification is relative to 
α5-overexpressing cells on FN-coated matrices. Arrows in C, E, G and I indicate peripheral localization of adhesion 
molecules. Results are the mean ± SEM of three separate experiments with 10–15 cells analyzed per each condition 
for each experiment. ***, p < 0.001. Scale bars: 50 μm.
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FIGURE 6: The α5β1-integrin adhesive bond enhances mechanotransduction in MECs. (A) Bar graphs showing adhesion 
strength of nonmalignant MECs expressing αv or α5 plated on recombinant FN 9–10 (FN 9–10 WT) and α5 plated on 
recombinant FN 9–10 with the synergy-site mutated (FN 9–10 Syn). (B) Immunofluorescence confocal images of 
MECs expressing α5 integrin plated on FN 9–10 WT or FN 9–10 Syn stained for p397FAK (green) and actin with 
phalloidin (F-actin; red). Scale bar: 10 μm. (C) Bar graph quantifying size of peripheral adhesions shown in B. 
(D) Immunofluorescence confocal images of MECs expressing α5 integrin plated on FN 9–10 WT or FN 9–10 Syn 
stained for vinculin. Scale bar: 3 μm. (E) Bar graphs showing quantification of relative amount of vinculin recruited to 
focal adhesions in MECs shown in D. (F) FRET images of MECs expressing α5 integrin and the vinculin force sensor 
plated on polyacrylamide gels conjugated with FN 9–10 WT or FN 9–10 Syn. Scale bar: 5 μm. (G) Bar graphs showing 
quantification of FRET index at focal adhesions in MECs shown in F. (H) Immunofluorescence confocal images of MECs 
expressing α5 integrin plated on FN 9–10 WT or FN 9–10 Syn stained for zyxin. Scale bar: 3 μm. (I) Bar graphs showing 
quantification of zyxin recruited to focal adhesions in MECs shown in H. (J) Immunofluorescence confocal images of 
MECs expressing α5 integrin plated on FN 9–10 WT or FN 9–10 Syn double-stained for zyxin and F-actin (Phalloidin). 
Scale bar: 3 μm. (K) Bar graphs showing quantification of zyxin colocalization to actin in MECs shown in J. 
(L) Immunofluorescence images of MECs expressing α5 integrin plated on FN 9–10 WT or FN 9–10 Syn stained for YAP. 
Scale bar: 15 μm. (M) Bar graphs quantifying percent nuclear YAP in MECs shown in I. For the immunofluorescence and 
FRET experiments, results are represented with the mean ± SEM of three separate experiments with either 10–15 cells 
(immunofluorescence analysis) or 25 cells (FRET analysis) analyzed per each condition for each experiment *, p < 0.05; 
***, p < 0.001.
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grown within rBM gels doped with either a 
recombinant 9–10 domain wild-type FN or 
recombinant 9–10 domain FN in which the 
synergy site was mutated and then assayed 
for colony morphology after 2 wk. Consis-
tent with the importance of synergy-site li-
gation and activation of the α5β1 integrin, in 
the absence of the synergy site, FN-ligated 
MECs formed small, growth-arrested acini in 
rBM (unpublished data) and failed to acti-
vate the hippo pathway, as revealed by lack 
of nuclear YAP (Figure 7A, right). By com-
parison, the MECs within rBM doped with a 
wild-type 9–10 FN grew to form large, disor-
ganized colonies and showed abundant nu-
clear YAP immunostaining (Figure 7A, left). 
To directly test the importance of the α5β1-
integrin adhesive bond in the tension-de-
pendent malignant behavior of mammary 
tissues, we studied the impact of the syn-
ergy site of FN in permitting stiffness-in-
duced MEC invasion in the 3D tension bio-
reactor doped with collagen–rBM–FN (see 
Figure 3) (Cassereau et al., 2015). Mammary 
colonies expressing high α5 integrin em-
bedded within the compliant (400 Pa) non-
stretched tension bioreactor remained qui-
escent and noninvasive (Figure 7B, left 
image, quantified in Figure 7C, left and 
right bar graphs). In response to uniaxial stretch and gel stiffening 
(4000 Pa), MECs from the colony invaded into the gel (Figure 7B, 
middle, see white arrows) and grew larger, as indicated by a signifi-
cant drop in colony circularity (Figure 7C, left bar graph) and an in-
crease in colony size (Figure 7C, right bar graph). However, inhibi-
tion of synergy-site binding, through treatment of the colonies with 
the small molecule ATN-161, prevented MEC invasion in response 
to ECM stiffness (Figure 7B, right, quantified in Figure 7C, left bar 
graph). The findings indicate that FN-ligated α5β1 integrin, by vir-
tue of its unique ability to bind to the FN synergy site, enhances cell 
tension to induce mechanosignaling that promotes the malignant 
behavior of MECs.
α5β1-integrin ligation by the RGD and synergy site of FN 
enhances MEC tension and promotes malignancy by 
amplifying growth factor–stimulated PI3K signaling
We next investigated how elevated cell tension mediated by liga-
tion of α5β1 integrin by FN promoted the malignant behavior of 
MECs. EGFR signaling enhances MEC growth and survival by acti-
vating PI3K and extracellular signal–regulated kinase (ERK) (Zahir 
et al., 2003; Yuan and Cantley, 2008), and oncogenic transformation 
requires PI3K and ERK signaling (Turner and Grose, 2010; Kandoth 
et al., 2013; Stephen et al., 2014). Consistently, we observed greatly 
reduced p202/204ERK and p473Akt levels in the mammary epithelium of 
Her2/Neu mice in which collagen cross-linking and ECM stiffening 
had been prevented by inhibiting LOX activity (Figure 8A) (Levental 
et al., 2009), and this reduction in PI3K and ERK signaling correlated 
with lower p397FAK, pMLC, α5-integrin, and FN expression in the tis-
sues (Figure 1B). Culture assays also showed that FN ligation of 
α5β1 integrin increased the levels and duration of EGFR-stimulated 
p473Akt and p202/204ERK activity in nonmalignant and malignant MECs 
(Supplemental Figure 4). Thus FN-ligated, nonmalignant HMT-3522 
S1 MECs expressing α5β1 integrin showed a 300% increase in 
significantly decreased when the MECs expressing higher α5 integ-
rin were plated on a recombinant 9–10 domain of FN in which the 
synergy site was mutated (Figure 6B, quantified in Figure 6C). Simi-
larly, the amount of the mechano-activated molecule vinculin that 
appeared to be recruited to the integrin adhesions was substantially 
reduced when the MECs were plated on an FN lacking the synergy 
site (Figure 6D, quantified in Figure 6E) (Dumbauld et al., 2010). 
Consistently, the vinculin fluorescent resonance energy transfer 
(FRET) index acquired using a vinculin FRET force sensor showed a 
significant decrease in tension applied to the vinculin molecule in 
the MECs plated on the 9–10 domain of FN with the mutant synergy 
site as compared with the wild-type domain (Figure 6F, quantified in 
Figure 6G) (Grashoff et al., 2010). The amount of zyxin, which is also 
force activated (Hirata et al., 2008; Hoffman et al., 2012), that was 
recruited to actin stress fibers and localized at the integrin adhesions 
was similarly reduced in the MECs expressing higher α5 integrin 
when they were plated on the recombinant FN lacking the PHSRN 
synergy domain (Figure 6, H–K). The importance of the α5β1-
integrin adhesive bond in enhancing mechanosignaling in MECs 
was illustrated by a dramatic reduction in nuclear YAP in the MECs 
ectopically expressing high α5 integrin plated on the 9–10 domain 
of FN in which the synergy site was mutated (Figure 6L, quantified in 
Figure 6M). These findings illustrate the importance of the FN syn-
ergy site for the engagement of the α5β1 integrin and the enhance-
ment of MEC tension subsequent to integrin adhesion maturation 
and increased cellular mechanosignaling.
α5β1-Integrin engagement by the RGD and synergy site of 
FN is required for the tension-dependent malignant 
behavior of MEC organoids
We next investigated the relevance of the α5β1-integrin adhesive 
bond in the tension-induced malignant behavior of mammary tis-
sues in culture. MECs ectopically expressing high α5 integrin were 
FIGURE 7: The α5β1-integrin adhesive bond is required for the tension-dependent malignant 
behavior of MEC organoids. (A) Immunofluorescence confocal images (bottom) and phase-
contrast images (top) of 3D cultures of α5/FN9–10 WT and α5/FN9–10 Syn. Site mutant 
nonmalignant MECs stained nuclear YAP. (B) Second harmonic generation images of 
nonmalignant (MCF10A) human mammary epithelial day 20 acini (green), expressing empty 
vector or elevated α5 integrin with FN and with or without FN synergy-site inhibitor, embedded 
in collagen (blue) and installed into a 3D tension bioreactor system and subjected either to 0% 
(400 Pa) or 10% (4000 Pa) stretch. Arrows in B indicate invasive cells, and colony circularity (left) 
and area (right) are quantified in C. Results are the mean ± SEM of three separate experiments 
with at least 10 acini analyzed per each condition each time. ***, p < 0.001,one-way ANOVA. 
Scale bars: 50 μm.
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disorganized phenotype toward differentiated nonmalignant MEC 
acini (Figure 8C, left bar graphs). Inhibition of either PI3K (Figure 8D, 
left bar graphs) or ERK activity (unpublished data) also significantly 
decreased the colony size of the HMT-3522 nonmalignant S1 MECs 
with FN-ligated α5β1 integrin. Treatment of malignant T4-2 MECs 
with the same PI3K (Figure 8C, right bar graphs) or ERK inhibitor 
(unpublished data) also reverted the malignant phenotype to that 
exhibited by noninvasive, growth-arrested, polarized, nonmalignant 
MEC acini and significantly decreased their colony size (Figure 8D, 
right bar graphs). Importantly, the α5β1 integrin–mediated increase 
p473Akt and a 200% increase in p202/204ERK 90 min after EGF treat-
ment compared with control cells expressing empty vector (Figure 
8B, left bar graphs). Similarly, treating malignant HMT-3522 T4-2 
MECs plated on FN with a function-blocking antibody to α5 integrin 
significantly decreased p473Akt and p202/204ERK activation in response 
to EGF (Figure 8B, right bar graphs). Nonmalignant S1 MECs cul-
tured in 3D rBM gels doped with FN formed disorganized, invasive, 
and nonpolarized colonies, yet inhibition of PI3K using a small-mol-
ecule inhibitor (LY294002, 5 µM) (Figure 8C, left bar graphs) or MAP 
kinase inhibitor (PD98059, 20 µM) (unpublished data) reverted their 
FIGURE 8: The FN synergy site–ligated α5β1 integrin increases MEC tension and promotes malignancy by amplifying 
PI3K signaling. (A) Confocal immunofluorescence images of pAkt substrate, pThr202/pTyr204ERK staining, and DAPI-stained 
nuclei of mammary tissue excised from 7-mo-old Her2/Neu transgenic mice (three mice/condition, three to five images 
per mouse used for analysis) treated with or without lysyl oxidase inhibitor (Lox). Scale bar: 10 μm. (B) Bar graphs 
showing level of p473Akt and pThr202/pTyr204ERK normalized to total cellular Akt and ERK in control or α5 integrin–
expressing nonmalignant HMT-3522 S-1 MECs and in T4-2 malignant MECs treated with either nonspecific IgG or a 
function-blocking antibody to α5 integrin at 90 min following EGF treatment. (C) Confocal immunofluorescence images 
of β4 integrin and β-catenin in colonies of control or α5 integrin–expressing nonmalignant HMT-3522 S-1 MECs and in 
T4-2 colonies treated with and without the PI3K inhibitor LY294002. Scale bar: 10 μm. (D) Bar graphs showing size of 
nonmalignant and malignant MEC colonies in C. (E) Line graphs showing time course of EGF-stimulated pThr202/pTyr204ERK 
(top) and p473Akt (bottom) levels normalized to total ERK and Akt in nonmalignant MCF10A MECs expressing elevated 
α5 integrin plated on wild-type (WT) or synergy site–mutated (Syn) FN. (F) Confocal images of nonmalignant MEC cells 
expressing elevated α5 integrin, a probe for PIP3 activity (mKO2-PH-Grp1), and the focal adhesion protein vinculin 
plated on recombinant 9–10 FN with (WT) or without (Syn) site mutated. Scale bar: 3 μm. Line graphs showing time 
course of quantification of EGF-stimulated PIP3 recruited to focal adhesions in nonmalignant MECs plated on wild-type 
(WT) or synergy site–mutated (Syn) FN. Measurements of all pixels in adhesions were averaged over the whole cell. 
Results are the mean ± SEM of three separate experiments for all studies; at least 10 cells/condition were used for each 
experimental repeat or 15–20 colonies/condition for 3D culture studies. ***, p < 0.001.
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FN, because this permits its critical adhesive bond activation, which 
is required to enhance cell tension and integrin mechanosignaling 
(Figures 3 and 4). Importantly, prior data showed that unfolding of 
FN reveals the otherwise hidden synergy site that permits the en-
gagement α5β1 integrin (Friedland et al., 2009; Seong et al., 2013). 
Our data expand upon these observations to imply that collagen-
mediated ECM stiffening could promote malignancy by fostering 
α5β1-integrin binding to the FN synergy site along stiff collagen fi-
brils that then permit the force-dependent exposure of the synergy 
site on FN molecules (Baneyx et al., 2002; Barker et al., 2005; 
Martino et al., 2009; Cao et al., 2012; Seo et al., 2015).
Tumors contain abundant quantities of type I collagen, and cross-
linked, remodeled type I collagen contributes critically to the tensile 
strength of a tissue (Levental et al., 2009; Lopez et al., 2011). Never-
theless, we failed to quantify differences in α2 integrin in either Her2/
Neu mouse mammary tissue or in the 3D organotypic cultures of 
malignant MECs in which the tension had been reduced (Figures 1 
and 2). Instead, we established a relationship among cell tension, 
ECM stiffness, and elevated expression of the FN receptor α5β1 in-
tegrin in mouse mammary tissue and mammary tumor organoids. 
We determined that MECs with FN-ligated α5β1 integrin, but not 
collagen I-ligated α2β1, exerted higher traction forces and were able 
to contract collagen gels better (Figure 5 and Supplemental Figure 
2). Our data are consistent with prior studies suggesting that α2β1 
integrin represses expression of the malignant phenotype of MECs 
in culture and is a tumor suppressor in the mammary gland in vivo 
(Zutter et al., 1995) and recent data indicating that α2β1 integrin 
activates FAK by a force-independent mechanism (Seong et al., 
2013). Interestingly, FN and collagen are often secreted and pro-
cessed in tandem (Ledger et al., 1980), and an FN matrix can serve 
as a scaffold to guide collagen assembly (Singh et al., 2010; Kubow 
et al., 2015). Indeed, just as FN deposition and unfolding requires a 
collagen scaffold, collagen assembly and remodeling require FN 
(McDonald, 1988; Dallas et al., 2005, 2006; Kadler et al., 2008), dur-
ing which time FN can be cross-linked to collagen (Eyre et al., 1984; 
Mosher, 1984). FN fibril assembly and collagen remodeling form a 
feedback loop, with collagen-mediated ECM stiffness and cell con-
tractility inducing conformational changes in FN that reveal hidden 
binding sites required for FN matrix assembly, which then further fa-
cilitate collagen remodeling (Baneyx et al., 2002; Li et al., 2003). 
Thus our data are consistent with a paradigm wherein the highly 
cross-linked collagen forms the scaffold upon which an FN mesh-
work is assembled. This stiffened ECM, by virtue of its ability to mod-
ify FN, would then favor tumor progression by permitting α5β1-
integrin binding to enhance tension-dependent signaling in tumors 
(Cao et al., 2012; Seo et al., 2015). Nevertheless, it is also feasible 
that FN-bound α5β1 integrin could collaborate with other trans-
membrane collagen receptors such as the discoidin domain receptor 
(DDR) or syndecans to foster malignant progression, particularly be-
cause DDRs are also tension regulated (Liebersbach and Sanderson, 
1994; Shyu et al., 2005; Shintani et al., 2008; Vuoriluoto et al., 2008).
PI3K and ERK regulate cell growth, survival, and invasion, and 
the levels and activity of these kinases are frequently elevated in 
tumors (McCubrey et al., 2007; Chappell et al., 2011). Accordingly, 
an assortment of pharmacological inhibitors have been developed 
to target these kinases and their associated signaling molecules to 
treat various solid cancers with various degrees of clinical success 
(McCubrey et al., 2008; Engelman, 2009; Wong et al., 2010; Thorpe 
et al., 2015). Here we determined that, while the Her2/Neu tumors, 
which are surrounded by a stiffened ECM, have elevated ERK and 
PI3K activity as expected, merely preventing collagen cross-linking 
and stiffening by inhibiting LOX activity significantly reduced both 
in PI3K signaling required ligation of the synergy site of FN, because 
nonmalignant α5β1 integrin–expressing MCF10A MECs showed a 
profound and sustained increase in EGF-stimulated Akt and ERK 
activation only when the cells were able to ligate a recombinant FN 
with an intact synergy site (Figure 8E).
A force-stabilized vinculin-talin-actin-zyxin scaffolding com-
plex facilitates PI3K-mediated conversion of phosphatidylinositol 
(3,4)-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-triphos-
phate (PIP3) (Rubashkin et al., 2014). We therefore asked whether 
the force-mediated stabilization of the vinculin-talin-actin-zyxin 
scaffolding complex by FN ligation of α5β1 integrin required en-
gagement of the FN synergy site to enrich PIP3 at integrin adhe-
sions. Consistently, a greater amount of mKO2-PH-Grp1 (a PIP3 
localization reporter; Martin-Belmonte et al., 2007) could be de-
tected at the focal adhesions (indicated by vinculin mEmerald) 
following EGF stimulation in the nonmalignant MCF10A MECs 
overexpressing the α5 integrin that were plated on recombinant 
9–10 FN domains, but only when the synergy site was intact 
(Figure 8F). These findings demonstrate that the engagement of 
an FN-ligated α5β1 integrin increases cell tension to stabilize a 
vinculin-talin-actin-zyxin scaffolding complex that is able to pro-
mote the malignant behavior of MECs by amplifying PI3K signal-
ing in response to EGFR stimulation.
DISCUSSION
Here we provide evidence that the FN associated with stiffened 
type I collagen fibers in the tumor microenvironment could foster 
malignant transformation and tumor progression by promoting the 
engagement of α5β1 integrin to increase tumor cell mechanosignal-
ing. The findings are consistent with previous data supporting the 
role of FN in mediating the cellular response to extracellular me-
chanical cues (Carraher et al., 2013). Our data suggest that the acti-
vation of FN-ligated α5β1 integrin provides the mechanical strength 
to transmit higher adhesion forces that promote the recruitment of 
vinculin, zyxin, and other focal adhesion proteins, which ultimately 
drive PIP nucleation at the plasma membrane to enhance growth 
factor–dependent PI3K signaling in the invading tumor cells. The 
data present a plausible explanation as to why a stiffened collagen 
ECM potentiates PI3K activation to promote tumor progression and 
provides insight into the relationship between the consistent up-
regulation of α5β1 and FN in many tumors as well as its association 
with metastasis. Using two-dimensional (2D) and 3D culture assays, 
a 3D tension bioreactor, and mouse models, we showed that FN-
ligated α5β1 integrin, by virtue of its ability to enhance cell tension 
through its synergy site, can promote expression of the malignant 
phenotype of MECs in vitro and in vivo. Our findings provide one 
perspective for why α5β1 integrin and its ligand FN are so frequently 
elevated in many solid tumors, where interstitial pressure and ten-
sion are also high, and in contractile primary and metastatic cancer 
cell lines and tumor cells, which have high Rho and ROCK activity 
(Maschler et al., 2005; Yao et al., 2007; Craig et al., 2009; Dingemans 
et al., 2010; Nam et al., 2010; Mierke et al., 2011; Yu et al., 2012). 
Our data are also consistent with prior results showing that cancer 
cell lines expressing abundant FN, when sorted for high membrane 
α5-integrin levels, migrate faster and contract collagenous matrices 
to a greater extent (Mierke et al., 2011), and studies showing that 
blocking the activity of RGD-binding receptors is critical for expres-
sion of the malignant phenotype of cultured breast cancer cells 
(Park et al., 2006; Nam et al., 2010). Here we not only identified 
α5β1 integrin as the key RGD receptor, but we also demonstrated 
that the ability of α5β1 integrin to promote the malignant pheno-
type of MECs requires binding to both the RGD and synergy site of 
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FN synergy site in tumor biopsies might be useful biomarkers to 
identify patients with potential kinase-treatment resistance (Barker 
et al., 2005).
MATERIALS AND METHODS
Antibodies and reagents
The following primary antibodies were used for our studies: colla-
gen IV, CIV 22, PCNA, and PC10 (DAKO); laminin-5 3-chain specific, 
BM165 (gift from M.P. Marinkovich, Stanford University); β1 inte-
grin, AIIB2 (gift from C.H. Damsky, Lawrence Berkeley National 
Laboratory); TS2/16 (American Type Culture Collection); β4 integrin 
3E1, ASC-3, ASC-8; α1 integrin FB12, α2 integrin 10G11, α4 integ-
rin P1H4,  α5 integrin SAM-1 and P1D6, α6 integrin GoH3, αv inte-
grin M9, FN, 3E3, E-cadherin, vinculin (Chemicon International); 
pAkt substrate, pMLCK Thr-18/Ser-19, YAP, activated caspase 3 
(Cell Signaling); pMypt Thr-850 (Millipore), pFak Tyr-397 (Invitrogen); 
Ki-67, β-catenin, Akt and pSer-472/473/474-Akt, Erk1 (BD Transduc-
tion Laboratories); p-Erk1/2 (Thr-202/Tyr-204) (New England Bio-
Labs); Flt-1/VEGFR1 antibody-1 (NeoMarkers). Phalloidin and anti-
mouse/rabbit/rat IgG secondary antibodies, conjugated with 
fluorescein isothiocyanate (FITC), Texas red (Jackson Laboratories), 
Alexa Fluor 488/555/647 (Invitrogen), and horseradish peroxidase 
(HRP; Amersham Pharmacia Biotech) were used. Inhibitors used 
were: EGFR-specific tyrosine kinase Tyrphostin AG 1478 (200 nM), 
MEK1: PD98059 (20 µM) and PI3K LY 294002 (20 µM) (BIOMOL), FN 
synergy-site inhibitor (50 µM; gift from A.P. Mazar). In addition, the 
following proteins were used: FN synergy-site mutants (gift from H. 
P. Erickson, Duke University), human recombinant VEGF Receptor 1 
Flt-1 (Oncogene), and RGD peptide (Biomol International).
Cell culture
HMT-3522, MCF10A MECs, and HDMVECs were grown and manip-
ulated in 2D and 3D rBM (Collaborative Research) and collagen ma-
trices. Phenotypic reversion of T4-2 cells was as previously described 
(Weaver et al., 1997). For inhibition of integrin function, the 3D mul-
ticellular structures were pre-incubated with anti-α2, α5, or αv integ-
rin–blocking antibodies or IgG isotype–matched control monoclonal 
antibody (mAb; 20 g IgG/ml). When added to 3D cultures, FN con-
centration was 50 µg/ml (WT and mutant FN were gifts of H. P. Erick-
son [Duke University] and were purified as described in Purification of 
FN domains 7–10). Colony size and morphology were measured af-
ter 10–12 d in culture. Inhibition studies were performed using 
ROCKi Y27632 (10 µM), PI3Ki LY294002 (5 µM), MAPKi PD98059 (20 
µM), EGFRi tyrphostin AG 1476 (100 mM). Adult human dermal mi-
crovascular endothelial cells (HDMVECs) were grown on collagen 
type I–coated flasks (Collaborative Biomedical) in EGM-2 bullet kit 
media (Bio-Whitaker). Angiogenesis induction by MECs was assayed 
by coculturing 3D rBM-generated mammary organoids in cell culture 
inserts (0.45-µm pore size; Biocoat; BD Labware) with HDMVECs that 
had been overlaid with a 1-micron layer of acellular collagen type I 
(BD Pharmingen). HDMECs invasion through the collagen overlay 
and network formation was assessed after 2 d by staining with tolu-
idine blue. Anchorage-independent growth was assessed using a 
soft agar assay. Briefly, 20,000 cells in 1.0 ml 0.35% agarose with or 
without integrin-blocking antibodies, as indicated, were overlaid 
with 1.0 ml 0.5% agarose containing 1X growth media, and colonies 
larger than 40 µm in diameter were scored positive after 21 d.
Cell and tissue staining
The 3D rBM gels, as well as tissue sections, were prepared by mix-
ing cultures with fresh collagen following embedment and freezing 
in sucrose with Tissue-Tek OCT compound (Miles Laboratories), 
ERK and Akt activity and did so in tandem with a reduction in 
α5 integrin and FN. We also observed that MECs with α5β1 integrin 
ligated by a wild-type, but not a synergy-site mutated FN, nucleated 
more vinculin-talin-actin-zyxin scaffold and recruited more PIP3 to 
amplify EGF-dependent activation of Akt and ERK. Inhibiting PI3K 
or ERK repressed the malignant behavior of FN-ligated mammary 
MEC 3D tissue-like structures expressing elevated α5β1 integrin 
(Figure 9). Our findings highlight the possibility that a stiffened tu-
mor ECM stroma could amplify oncogenic signaling by enhancing 
EGFR signaling through PI3K and ERK via ligation of α5β1 integrin 
by the FN synergy site. The net result would be a reduced efficacy 
of many of the therapies targeting this pathway, as has been re-
cently demonstrated (Hirata et al., 2015). The data thereby provide 
one plausible explanation for why, in some instances, targeted 
molecular therapies are less effective and suggest that combinato-
rial treatments that target both the mechanical properties of the cell 
or tissue and specific oncogenic signaling pathways might prove to 
be a better therapeutic option (Sanz-Moreno et al., 2011; Calvo 
et al., 2013; Sadok et al., 2015; Jiang et al., 2016; Laklai et al., 2016). 
Our findings are therefore clinically relevant, as they identify a tu-
mor-specific mechanical signature, because the synergy site is only 
engaged in a high-force environment, such as in a wound or at the 
invasive front of a tumor. Thus inhibiting the ability of α5β1 integrin 
to ligate the synergy site of FN could prove to be a tractable cancer-
specific therapy (Garcia et al., 1998; Baneyx et al., 2002). The data 
also suggest that new tools that are being developed to detect the 
FIGURE 9: Model describing how ligation of α5β1-integrin synergy 
site promotes MEC malignancy. When tumor cells encounter FN-rich, 
stiff collagen fibers at invasive fronts, they engage the α5β1-integrin 
synergy site to recruit vinculin and zyxin to sites of focal adhesions in 
a tension-dependent manner to nucleate PIP3 at the plasma 
membrane and enhance PI3K–dependent tumor cell invasion.
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Her2/Neu mice were treated starting at 5 mo of age with BAPN 
(3 mg/kg; Spectrum) in the drinking water or a LOX function–block-
ing polyclonal antibody (3 mg/kg; OpenBiosystems) injected intra-
peritoneally twice per week (Levental et al., 2009). Mice were killed 
at 7–8 mo of age, at which time the fourth mammary gland was PFA 
fixed, paraffin sections were analyzed for histology, and parallel sec-
tions were stained as described.
PyMT mice were treated with BAPN (3 mg/kg; Spectrum) in the 
drinking water starting at 4 wk of age. The mice were killed at 14 wk 
of age with the tumors being harvested for PFA fixation and paraffin 
embedding for staining as described.
Four-week-old BALB/c nu/nu mice were subcutaneously injected 
in the rear flanks (5E6 cells/injection, together with Matrigel with or 
without addition of function-blocking antibody or IgG isotype con-
trol). Tumor development was monitored via external palpation, and 
lesions were measured and monitored biweekly for 2 mo upon detec-
tion (instant readout digital calipers; Electron Microscopy Sciences).
Retroviral and lentiviral infections and vectors
Standard retroviral and lentiviral infection procedures were used. For 
detailed descriptions of lentiviral and retroviral constructs and vec-
tors, please refer to the Supplemental Experimental Procedures.
Western and ELISA procedures
Equal amounts of cell protein lysate (either RIPA or Laemmli lysate; 
BCA; Pierce) were separated on reducing SDS–PAGE gels, trans-
ferred to nitrocellulose or polyvinylidene fluoride membranes, and 
probed with primary antibody. Bands were visualized and quantified 
using a Fujifilm Gel Documentation system in combination with 
HRP-conjugated secondary antibodies and ECL-Plus system (Amer-
sham Pharmacia). Specific activity for Akt and Erk was calculated by 
normalizing densitrometric values of phosphorylated to total AKT or 
ERK and E-cadherin. Integrin protein levels were assessed using 
nonreducing SDS–PAGE gels. VEGF, Il-8, and bFGF levels in the 
media of 10- to 12-day 3D rBM cultures of MECs were measured 
using sandwich ELISA (R&D Systems), according to the manufactur-
er’s instructions. OD measurements were performed using a Fluo-
roskan Ascent FL (Labsystems).
Real time-PCR analysis
Random-primed cDNA was prepared from total isolated RNA using 
Trizol reagent (Invitrogen), and target cDNA sequences were quanti-
fied via real-time PCR using SYBR Green I reagent (Roche) according 
to the manufacturer’s protocol. An Eppendorf Realplex2 quantita-
tive PCR machine was used for all studies.
Real time-PCR primers
The following primer sequences were used: 18S: forward 5′-cggctac-
cacatccaaggaa-3′, reverse 5′-gctggaattaccgcggct-3′; FN 1: forward 
5′-agtgggagacctcgagaag-3, reverse 5′-gtccctcggaacatcagaaa-3′, 
5′-agtgggagacctcgagaag-3′, reverse 5′-gtccctcggaacatcagaaa-3′, 
VEGF: forward 5′-caggctgcacccatggcagaa-3′, reverse 5′-gcatcgcat-
caggggcacaca-3′.; ITGB1: forward 5′-cgaggtcatggttcatgttg-3′, re-
verse 5′-tcccatttggcattcatttt-3′; ITGA5: forward 5′-agcctcagaaggag-
gaggac-3′, reverse 5′-ggttaatggggtgattggtg-3′, ITGA2 forward 
5′-tgaccaaattctgcaggaca-3′, reverse 5′-ggagccaatctggtcacct-3′; 
ITGAV forward 5′-ccaccaagctttggctattc-3′, reverse 5′-caggcagtgag-
caggtttta-3′.
Cell contractility, migration, and durotaxis assays
Collagen gel contraction was measured by imaging projected 
gel areas of cell-embedded collagen gels as described previously 
then sectioning them in 10- to 20-µm-thick slices for analysis. All 
samples were incubated with primary mAbs followed directly by 
either FITC-, Texas red-, or Alexa Fluor–conjugated secondary 
antibodies and DAPI, when indicated. Nuclei were counterstained 
with diaminophenyl-indole (Sigma-Aldrich). Images were compared 
and quantified based on fluorescence intensity signal following min-
imal thresholding to subtract background. For mouse studies, when 
mice were killed, lesions were photographed, dissected, measured, 
macroscopically analyzed, fixed in 4% paraformaldehyde (PFA), and 
paraffin embedded. H&E sections were evaluated for histopatho-
logical evidence of tumor phenotype, and tissue sections were ana-
lyzed by immunofluorescence as described.
Image acquisition and analysis
All immunofluorescence images were recorded at 20–120× magnifi-
cation and conventional images were recorded at 40–60× magnifi-
cation. FRET images were acquired using a 60×/WI 1.2 NA Plan-Apo 
objective. Immunofluorescence and FRET images were acquired 
using an Olympus IX81 epifluorescence microscope with Spot color 
CCD camera, Nikon TE2000-U inverted microscope, Bio-Rad MRC 
1024 laser-scanning confocal microscope attached to a Nikon Dia-
phot 200 microscope, and a spinning-disk/ total internal reflection 
fluorescence (TIRF) microscope setup with Andor’s iXon3 EMCCD 
camera with the Yokogawa CSU-X1 confocal scanner, a Nikon TIRF 
illuminator, and a MOSAIC module for fluorescence recovery after 
photobleaching (FRAP) and photoactivation on a motorized Nikon 
Ti-E inverted microscope base. Where immunofluorescence inten-
sity was quantified, images were taken using identical image-acqui-
sition parameters and were immunostained using the same primary 
and secondary antibody solutions. Images were imported into Im-
ageJ (NIH), and positive signal was thresholded to secondary-only 
controls. The thresholded images are quantified from positive signal 
and presented as mean pixel density per group of samples.
The 3D tension bioreactor
PyMT organoids were cultured in rBM (Corning) for 3–5 d. The organ-
oids were isolated by solubilizing the gels using phosphate-buffered 
saline (PBS)-EDTA. The isolated organoids were subsequently embed-
ded in 2.5 mg/ml collagen I solution supplemented with FN (1 µg/ml). 
The collagen gels were stretched in a tension bioreactor with 0% or 
10% strain for 72 h (Cassereau et al., 2015). Organoids were fixed with 
4% PFA overnight for subsequent immunofluorescence staining.
Flow cytometry
Cells were isolated, blocked with 1% bovine serum albumin (BSA) in 
PBS for 60 min, incubated with saturating concentrations of primary 
mAb for 60 min, washed three times, and labeled with FITC- or 
phycoerythrin-conjugated goat IgG (Millipore). Stained cells were 
washed three times and immediately analyzed on a FACScan (BD 
Pharmingen). All manipulations were conducted at 4°C.
PIP3 localization analysis
Stable lines of MCF10A cells expressing tagged α5 integrin and 
transiently transfected with vinculin-mEmerald and KO2-PH-Grp1 (a 
fluorescent PIP3 probe courtesy of Keith Mostov) were plated on 
recombinant FN 9–10 or recombinant FN 9–10 with the synergy-site 
mutants. For analysis methods used, refer to the Supplemental Ex-
perimental Procedures.
Mouse studies
Cohorts of PyMT and FVB mice were maintained in accordance with 
University of California IACUC guidelines under protocol AN092125.
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Patterned substrates were coated with purified adhesive ligands 
(20 µg/ml), blocked with 1% heat-denatured BSA, incubated in PBS 
(Ca2+/Mg2+), then seeded with cells at a density of 210 cells/mm2, 
and incubated for 16 h at 37°C.
Cell adhesion assay description. Cell adhesion to FN-coated is-
lands was measured using a hydrodynamic spinning-disk system. 
Micropatterned substrates with adherent cells were spun in PBS 
supplemented with 2 mM dextrose for 5 min at constant speeds. 
The applied shear stress (τ) is given by the formula τ = 0.8r(ρµω3)1/2, 
where r is the radial position and ρ, µ, and ω are the fluid density, 
viscosity, and rotational speed, respectively. After being spun, cells 
were fixed in 3.7% formaldehyde, permeabilized in 1% Triton X-100, 
and stained with ethidium homodimer-1 (Invitrogen). Adherent cells 
were counted at specific radial positions using a 10× objective lens 
in a Nikon TE300 microscope equipped with a Ludl motorized 
stage, Spot-RT camera, and an Image-Pro analysis system. A total of 
61 fields (80–100 cells per field before spinning) were analyzed, and 
cell counts were normalized to the number of cell counts at the 
center of the disk. The fraction of adherent cells (f) as a function of 
shear stress τ (force/area) was then fitted to a sigmoid curve f = f0/[1 
+ exp[b (τ − τ50)]], where τ50 is the shear stress for 50% detach-
ment, b is the inflection slope, and f0 is the y-intercept. τ50 repre-
sents the mean adhesion strength for the cell population.
Vinculin tension sensor and FRET
FRET images were collected and analyzed as previously described 
(Graham et al., 2001). Briefly, images were background subtracted 
and adjusted for spectral bleedthrough. Relative FRET index was 
calculated by taking the ratio of pixel intensity in the FRET image 
(donor excitation and acceptor emission) to pixel intensity in the 
donor image (donor excitation and emission). Average cell FRET 
index was calculated for each cell in a sample of 25–30 cells. Cell 
averages were then used to calculate a sample average, which was 
then used in Student’s t tests to evaluate whether the sampled pop-
ulations had different means.
Purification of FN domains 7–10 (wild-type, double, and 
triple synergy-site mutants)
BL21(DE3) bacteria transformed with pET constructs expressing 
wild-type human FN domains 7–10 (Fn7-10) and the double 
(R1374A/R1379A) and triple (R1374A/P1376A/R1379A) synergy-site 
mutants were generous gifts of H. P. Erickson (Duke University). Bac-
teria were grown to an OD600 of 0.5–0.6 in 125 ml of 2× YT with 
50 µg/ml ampicillin at 37°C in a shaking incubator, and expression 
was induced for 2–3 h by addition of IPTG to 0.4 mM. Bacteria were 
pelleted and resuspended on ice in 5 ml of 0.2 µg/ml lysozyme in 
50 mM Tris-HCl/100 mM NaCl/1 mM EDTA, pH 8 (at 4°C). MgCl2, 
DNAseI, and PMSF were added to final concentrations of 10 mM, 
190 U/ml, and 1 mM, respectively, and bacteria were digested for 
30 min with stirring on ice. Lysis was effected by addition of Triton 
X-100 0.1% and sonication with two 30-s bursts. The supernatant 
containing soluble Fn7–10 was obtained by centrifugation for 30 min 
at 15,000 × g (at 4°C) and precipitated by addition of solid ammo-
nium sulfate to 40% saturation (at 4°C). Following centrifugation for 
30 min at 15,000 × g, the pelleted fraction was redissolved in 10 ml 
of 20 mM Tris-HCl, pH 7.9 (at 4°C). Redissolved proteins were filtered 
(0.22-µm pore size) and loaded at 1 ml/min onto a 1.6 cm × 10 cm 
Q-Sepharose HP (GE Healthcare) column equilibrated in 20 mM Tris-
HCl, pH 7.9 (at 4°C) and washed in the same until OD260 returned to 
baseline. Bound proteins were eluted by a linear gradient of 0–0.5 M 
NaCl over 100 min, and 5-ml fractions were collected. Fractions 
(Asaga et al., 1991). Traction-force microscopy studies were per-
formed as described by Dembo and colleagues and processed us-
ing LIBTRC-2.0 software (Dembo and Wang, 1999; Reinhart-King 
et al., 2003). For durotaxis studies, bright-field images were cap-
tured every 5 min over 12 h using gradient-stiffness polyacrylamide 
gel (Isenberg et al., 2009). Cell migration time-course images were 
compiled, and cell speed, persistence, distance, and directionality 
were analyzed on a single-cell basis with ImageJ (NIH) and the Che-
motaxis plug-in (Meijering et al., 2012).
Substrate preparation
ECM–cross-linked PA gels were prepared and mechanically ana-
lyzed as described; single stiffness substrates and mechanically gra-
dient substrates (Lakins et al., 2012) with modifications made as 
described in Przybyla et al. (2016). Briefly, two droplets, each con-
taining 12.5 µl of a soft (100 Pa) or stiff (60,000 Pa) acrylamide/bis-
acrylamide mixture, were placed adjacent to each other on a large 
hydrophobic coverglass (no. 1, 45 mm × 50 mm; Fisher Scientific) 
and then covered with a small circular activated coverglass (no. 1, 
18-mm diameter; Fisher Scientific) to merge the drops. By carefully 
maintaining the interface, a uniform gradient of 3.33Pa/µm along 
the length of substrate was achieved. Regions of different rigidities 
were distinguished by using a fluorescently labeled bis-acrylamide 
in the stiff solution creating a gradient of fluorescence correlated 
with the mechanical gradient.
Substrate elastic modulus was measured via atomic force micros-
copy (Asylum Research) using the Hertz model. Briefly, a silicon 
beaded–tip cantilever (5-µm diameter, 0.07 N/m, silicon nitride) was 
used to measure 90 × 90 µm elastic modulus maps down the length 
of the gel along the mechanical gradient while simultaneously mea-
suring fluorescence intensity with a inverted epifluorescence micro-
scope. We used these measurements to assess the mechanical gra-
dient and develop an algorithm for determining the elastic modulus 
of the gel solely from the fluorescence intensity. This model allowed 
us to determine the particular surface stiffness seeded cells were 
adhered to when tracking cell motility.
Adhesion strength assay and generation of recombinant FN
Preparation of adhesive ligands: the previously described Promega 
Pinpoint vector containing the sequence for a fragment spanning 
the 7th to 10th type III repeat of human FN (FN7–10) was cut with 
NruI and ligated to yield an expression vector for a fragment 
spanning the 9th to 10th type III repeat of human FN (FN9–10). The 
synergy-site mutant PHSAN [FN9–10(PHSAN)] was generated using 
the Stratagene QuikChange Site-Directed Mutagenesis kit and prim-
ers 5′-GGGTGCCCCACTCTGCGAATTCCATCACCC-3′ (forward) 
and 5′-GGGTGATGGAATTCGCAGAGTGGGGCACCC-3′ (reverse). 
Constructs were verified by DNA sequencing. Proteins were ex-
pressed in JM109 cells (Promega) in the presence of d-biotin and 
purified by affinity chromatography. Protein concentration and purity 
were confirmed by Western blotting and Coomassie blue staining.
Preparation of micropatterned substrates. Micropatterned sub-
strates were generated by microcontact printing of self-assembled 
monolayers of alkanethiols on gold using a polydimethylsiloxane 
(PDMS) stamp (Sylgard 184/186 elastomer kit) with circular patterns 
(10-µm-diameter circles, 75-µm center-to-center spacing). Arrays of 
methyl-terminated alkanethiol [HS-(CH2)11-CH3; Sigma-Aldrich] 
circles were stamped onto Au-coated glass coverslips. The remain-
ing exposed areas were functionalized with a tri(ethylene glycol)-
terminated alkanethiol [HS-(CH2)11-(CH2CH2O)3-OH; ProChimia 
Surfaces] to generate a cell adhesive–resistant background. 
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containing wild-type and mutant forms of Fn7–10 were identified by 
SDS–PAGE and staining with Coomassie blue and eluted between 
0.26 and 0.35 M NaCl. Peak fractions were pooled and desalted by 
exhaustive dialysis against PBS and sterilized by filtration through 
0.22-µm syringe filters. Purified Fn7–10 concentrations were esti-
mated by micro-BCA Assay (Pierce Chemical).
Doxycycline-inducible expression of α integrins
For HMT3522 cell lines S1 and T4-2, α5 and α2 integrins were 
cloned and expressed as doxycycline-inducible eGFP fusions in the 
retroviral vector pHRS puro Tet MCS. pHRS puro Tet MCS features in 
reverse orientation, an expression cassette for puromycin acetyl-
transferase back to back with a hepatamerized TetO minimal cyto-
megalovirus (CMV) promoter downstream of which α-integrin fu-
sions were cloned. After transduction and selection for puromycin at 
1 µg/ml, resistant cells were transduced with the recombinant retro-
virus generated from MFG tTA, which constitutively expresses the 
TETOFF transcriptional transactivator form the 5′LTR. Transduced 
cells were induced by withdrawal of doxycycline for 2 d and sorted 
by flow cytometry for eGFP-positive cells to obtain a more homoge-
neous population of α5 and α2 integrin–overexpressing cells. For 
MCF10A cells, overexpressing lines were prepared using recombi-
nant lentiviruses. Expression of the synthetic reverse tetracycline 
transactivator (TETON) rtTAs-M2 was obtained by transduction of 
target cells with the lentiviral vector pLV rtTAs-M2 IRES Neor. In pLV 
rtTAs-M2 IRES Neor, rtTAs-M2 is under control of the human EEF1α 
promoter and is coexpressed with neomycin phosphotransferase via 
a bicistronic (IRES-mediated) mRNA. Transduced cells were selected 
with 250 µg/ml G418. The complete coding regions (cds) of human 
α5 and α2 integrins were subcloned into the lentiviral vector pLV 
puro Tet MCS. PCR was used to introduce a Kozak concensus se-
quence to the 5′ ends of the cds and at the 3′ end to remove the 
stop codon and enable in-frame fusion to five tandem repeats of the 
myc epitope recognized by mAb 9E10 followed in frame by TagRFPT 
fluorescence protein. α-Integrin fusions were cloned downstream of 
the hepatamerized TetO minimal CMV promoter in pLV puro Tet 
MCS. pLV puro Tet MCS expresses puromycin acetyltransferase from 
an internal expression cassette in reverse orientation, and trans-
duced G418r rtTAs-M2–expressing cells were selected with puromy-
cin at 1 µg/ml. Following selection, expression of integrins was ob-
tained by induction with doxycycline and a more homogeneous 
expressing population was obtained by flow sorting for TagFPT-pos-
itive cells.
Statistical analysis
Statistical analysis was performed using Prism/GraphPad Soft-
ware (La Jolla, CA) at indicated p values. Unless otherwise stated, 
two-tailed Student’s t tests were used for significance testing to 
compare mean differences between two conditions, and one-way 
analysis of variance (ANOVA) was used to compare means of 
more than two conditions. Means were presented as ±SEM of at 
least three independent experiments. Where indicated, sample 
size, n, refers to either the number of animals (for animal studies 
with indicated number of images analyzed per animal, and unless 
otherwise indicated, three to five images were analyzed per ani-
mal) or the number of times each experiment was repeated (for all 
in vitro studies, at least 10 cells per condition were analyzed for 
each replica). Statistical significance was considered at p < 0.05 
and was calculated only for experiments with a sample size of at 
least three. Adhesion-strength values were specifically analyzed 
via ANOVA and Tukey’s post hoc test with a p value < 0.05 con-
sidered significant.
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